Cardioprotection of (±)-sodium 5-bromo-2-(α-hydroxypentyl) benzoate (BZP) on mouse myocardium I/R injury through inhibiting 12/15-LOX-2 activity
作者:Yue Xiao、Chuanjun Song、Qiao Lin、Xiaojing Shi、Wenquan Yu、Xin Huang、Huimin Wang、Yang Chen、Ruiyong Wang、Xuepeng Geng、Mingyang Qin、Kaizhao Hu、Yilin Fan、Yan Qiao、Erhe Gao、Wen Zhao、Junbiao Chang
DOI:10.1016/j.yjmcc.2019.07.014
日期:2019.10
(+/-)-Sodium5-bromo-2-(alpha-hydroxypentyl) benzoate (brand name: brozopine, BZP, la), derived from L-3-n-butylphthalide (L-NBP), has been reported to protect the brain from stoke and has been approved by CFDA in Phase I-II clinical trials. However, it remains to be investigated whether 1a may exhibit any cardioprotective effect on ischemia-reperfusion (I/R) injury. In the current study, C57BL/6 and ICR mice were pretreated with 1a, and myocardium I/R were then performed. We found that la not only significantly reduced the infarct size and improved cardiac contractile function after acute MI/R in both species, but also protected hearts from chronic MI-related cardiac injury. Mechanically, we found that la physically binds to 12/15-LOX-2 using molecular docking. The shRNA-mediated 12/15-LOX-2 knockdown almost completely blocked the protective effect of 1a. Our findings, for the first time, strongly indicate that la may serve as a potent and promising cardioprotective agent in treatment of I/R related injury, at least partially through targeting 12/15-LOX-2.
(±)-L-3-n-丁基酞酰乙酸衍生物(brand name: brozopine, BZP, la),来源于L-3-n-butylphthalide(L-NBP),据报道可保护大脑免受中风的伤害,并已在一期到二期临床试验中获得CFDA批准。然而,仍需研究1a是否可能对缺血-再灌注(I/R)损伤具有心肌保护作用。在本研究中,C57BL/6和ICR小鼠预先用1a处理,然后进行心肌I/R手术。我们发现,la不仅在两个物种中显著减少了急性MI/R后的梗死面积并改善了心脏收缩功能,还保护心脏免受慢性MI相关的心脏损伤。在机制上,我们发现通过分子对接,la能够物理结合12/15-LOX-2。12/15-LOX-2的shRNA介导的敲除几乎完全阻断了1a的保护作用。我们的研究结果首次强烈表明,la可能作为一种强效和有前途的心脏保护剂,用于治疗I/R相关损伤,至少部分通过靶向12/15-LOX-2。